Curative Treatment for Oligometastatic Gastroesophageal Cancer
Author Information
Author(s): Norén N., Rouvelas I., Lundell L., Nilsson M., Sunde B., Szabo E., Edholm D., Hedberg J., Smedh U., Hermansson M., Lindblad M., Klevebro F.
Primary Institution: Karolinska Institutet
Hypothesis
Can combined systemic and local treatment with curative intent be safely administered to patients with oligometastatic gastroesophageal cancer?
Conclusion
Curative treatment for oligometastatic gastroesophageal cancer is relatively safe, with an overall survival of 20.8 months and no postoperative mortality.
Supporting Evidence
- 29 out of 35 patients completed the treatment.
- Postoperative complications occurred in 73.1% of patients, but there was no postoperative mortality.
- Median overall survival was 20.8 months from diagnosis.
Takeaway
Doctors are trying a new way to treat some stomach and esophagus cancers that have spread, and it seems to help people live longer without dying from surgery.
Methodology
This was a prospective multicenter cohort study involving patients with oligometastatic gastroesophageal cancer who received perioperative chemotherapy followed by surgical resection or liver ablation.
Potential Biases
Potential biases due to the non-randomized nature of the study and missing data.
Limitations
The study had a non-randomized design, a heterogeneous patient group, and a limited sample size.
Participant Demographics
The median age was 66 years, with 65.7% male participants.
Statistical Information
P-Value
0.035
Confidence Interval
11.2–42.6
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website